TQ-B3101

TQ-B3101 · Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Drug timelines are a Plus or Pro feature.

2 regulatory and trial events tracked for TQ-B3101, covering 2019-08-15 to 2020-03-13. Get the full timeline:

Most recent: Clinical Trial Update: A Study of TQ-B3101 in Subjects With Relapsed or Refractory Anaplastic Large Cell Lymphoma (ALCL) [Phase 2]